We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$558M
AUM Growth
+$54.7M
Cap. Flow
+$23.7M
Cap. Flow %
4.24%
Top 10 Hldgs %
57.55%
Holding
51
New
14
Increased
7
Reduced
11
Closed
13

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$33.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$15M
4
PCRX icon
Pacira BioSciences
PCRX
+$13.9M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$13.8M

Top Sells

Rank Stock Value
1
TXMD icon
TherapeuticsMD
TXMD
+$24.9M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$15.2M
3
RXDX
Ignyta, Inc.
RXDX
+$10.7M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$10.4M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 79.15%
2 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
$41.2M 7.37%
+2,439,930
New +$33.5M
ADMS
2
DELISTED
Adamas Pharmaceuticals
ADMS
$38.8M 6.94%
2,216,351
-385,000
-15% -$6.37M
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$307M
$36.4M 6.52%
2,232,238
– –
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$35.4M 6.34%
2,440,959
– –
PTCT icon
5
PTC Therapeutics
PTCT
$5.64B
$34.8M 6.24%
1,900,000
+431,479
+29% +$5.81M
SGYP
6
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$32.1M 5.76%
7,223,509
– –
CNCE
7
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$27.9M 5%
2,000,000
-200,000
-9% -$2.95M
NBIX icon
8
Neurocrine Biosciences
NBIX
$16.8B
$27.6M 4.94%
600,000
+40,000
+7% +$1.94M
RIGL icon
9
Rigel Pharmaceuticals
RIGL
$681M
$24.9M 4.45%
910,569
– –
FOMX
10
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$22.2M 3.97%
4,781,708
+1,100,000
+30% +$4.91M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$27.5B
$22.1M 3.96%
276,800
+265,283
+2,303% +$17M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$19.4M 3.48%
243,800
-58,009
-19% -$4.19M
RNAC icon
13
Cartesian Therapeutics
RNAC
$229M
$18.6M 3.34%
+31,250
New +$13.8M
RXDX
14
DELISTED
Ignyta, Inc.
RXDX
$18.1M 3.24%
1,749,323
-1,321,977
-43% -$10.7M
DBVT
15
DBV Technologies
DBVT
$799M
$17.9M 3.2%
50,000
+1,408
+3% +$481K
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$15M 2.69%
493,500
+193,500
+65% +$5.61M
PCRX icon
17
Pacira BioSciences
PCRX
$1.04B
$14.3M 2.56%
+300,000
New +$13.9M
SGEN
18
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$12.9M 2.31%
+249,500
New +$15.9M
PTLA
19
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$12.1M 2.18%
+216,200
New +$8.66M
NDRM
20
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$9.3M 1.67%
311,000
-3,724
-1% -$96.5K
INSM icon
21
Insmed
INSM
$21.4B
$9.24M 1.66%
+538,473
New +$9.2M
AIMT
22
DELISTED
Aimmune Therapeutics
AIMT
$8.95M 1.6%
435,402
+312,947
+256% +$5.97M
LUMO
23
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.03M 1.44%
+121,428
New +$15M
APYX icon
24
Apyx Medical
APYX
$173M
$7.22M 1.29%
2,924,015
-130,985
-4% -$322K
AMRN
25
Amarin Corp
AMRN
$299M
$7.13M 1.28%
+88,500
New +$5.5M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Great Point Partners held 51 positions worth $558M, up 11% from $504M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners deployed $23.7M of net new capital in Q2 2017, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 2,439,930 shares worth $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ignyta, Inc., an estimated $10.7M trimmed.

  • Great Point Partners's largest Q2 2017 buy was Arena Pharmaceuticals Inc: 2,439,930 shares worth $41.2M.
  • Great Point Partners added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $17M increase.
  • Great Point Partners's biggest Q2 2017 reduction was Ignyta, Inc., cutting an estimated $10.7M.
  • Great Point Partners fully exited TherapeuticsMD in Q2 2017, selling an estimated $24.9M.
  • Great Point Partners's ten largest holdings make up 58% of its $558M portfolio in Q2 2017.
  • Great Point Partners opened 14 new positions and closed 13 in Q2 2017.
  • Great Point Partners's portfolio value rose 11% quarter-over-quarter to $558M.

Based on Great Point Partners's 13F filing for Q2 2017, filed 14 Aug 2017.